Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Emergency Surgery
  •  Colon and Rectal Surgery
  •  Orthopaedic Surgery
  •  Plastic Surgery
  •  Cardiovascular Surgery
  •  Breast Surgery
  •  Robotic Surgery
  •  Gastroenterological Surgery


Citation: Clin Surg. 2020;5(1):2788.Research Article | Open Access

Perioperative Management of Patients Undergoing CRS and HIPEC

Akhil Chawla1, Cheng-Cheng Zhu2, Grant Backer3, Julia O’Gara3, Zhi ven Fong3, Hao M Deng2, Xiaodong Bao2, James C Cusack3*

1Department of Surgery, Division of Surgical Oncology, Northwestern University Feinberg School of Medicine, USA
2Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, USA
3Department of Surgery, Division of Surgical Oncology, Massachusetts General Hospital, USA

*Correspondance to: James C. Cusack 

 PDF  Full Text DOI: 10.25107/2474-1647.2788


Background and Objectives: We conducted a retrospective review to assess the outcomes of our initial five-year experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Massachusetts General Hospital. Methods: A prospective database was maintained to understand the effect of our multidisciplinary approach using a dedicated perioperative anesthesia and nursing team and goal-directed fluidrestrictive resuscitation for CRS and HIPEC performed with 40 mg of mitomycin C at 42°C for 90 min. ERAS protocol included strict fluid-replacement guidelines, early ambulation, and early resumption of enteral intake. Results: We performed 97 cases from 2011-2016. The median PCI was 14.5. Completeness of Cytoreduction score was 0 or 1 in 88.5%. Patients had a median estimated blood loss of 300 mL with a transfusion requirement in 14.4% of patients. 88.7% of patients were extubated immediately postoperatively. The intraoperative complication rate was 4.1%. The median ICU and hospital stays were 2 and 8 days, respectively. The 30-day readmission rate was 16.5%. The 90-day mortality rate was 0%. Conclusion: The outcomes from our initial experience using a multidisciplinary approach in patients undergoing CRS and HIPEC demonstrate short postoperative ICU and hospital stays, acceptable postoperative morbidity and readmission rates, and low perioperative mortality.


Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Pseudomyxoma peritonei; Enhanced recovery after surgery

Cite the article

Chawla A, Zhu C-C, Backer G, O'Gara J, Fong ZV,Deng H, Bao X, Cusack J. Perioperative Management of Patients Undergoing CRS and HIPEC. Clin Surg. 2020; 5: 2788.

Search Our Journal

Journal Indexed In

Articles in PubMed

Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
Mesh Sprayer Device with Liquefied Mesh Delivery System: Proposed Alternative for Currently Available Meshes in Hernia Repair and Supplement to Abdominal Closure
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Site-Specific Response of Bone Tissue to Ovariectomy in a Rabbit Model
 Abstract  PDF  Full Text
Recurrent and Refractory Ischemic Stroke Complicating Evans Syndrome
 Abstract  PDF  Full Text
View More...